I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 11/25/02

Attorney Docket No.: 02307O-103031US

Client Reference No.: 1992-383-6

RECEIVED

DEU 0 5 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NOBORI et al.

TOWNSEND and TOWNSEND and CREW LLP

Application No.: 09/780,114

Filed: February 9, 2001

For: METHOD FOR DETECTION OF THE PRESENCE OR ABSENCE OF **METHYLTHIOADENOSINE** PHOSPHORYLASE (MTASE) IN A CELL SAMPLE BY DETECTION OF THE PRESENCE OR ABSENCE OF MTASE ENCODING NUCLEIC ACID IN THE CELL SAMPLE

Examiner: Jeanine Anne Goldberg

Art Unit: 1634

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

PATENT

NOBORI et al.

Application No.: 09/780,114

Page 2

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Beth L. Kelly Reg. No. 51,868

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 415-576-0200 Fax: 415-576-0300

BLK/llc

SF 1408604 v1

2 (3)		Application Number	09/780,114 DF1
🎒 TRANSMI'		Filing Date	February 9, 2001
FORM	1	First Named Inventor	r Nobori, Tsutomu TECH CEN
(to be used for all corresponde	nce after initial filing)	Group Art Unit	1634
		Examiner Name	Jeanine Anne Goldberg
Total Number of Pages in This S	ubmission 4	Attorney Dock	per 02307O-103031US
·	ENCL	OSURES (check all that a	oply)
Fee Transmittal Form	Transmittal Form Assign		After Allowance Communication to Group
Fee Attached	☐ Drawi	ng(s)	Appeal Communication to Board of Appeals and Interferences
Amendment / Reply	Licens	sing-related Papers	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petitio	on	Proprietary Information
Affidavits/declaration(s	<u></u>	on to Convert to a sional Application	Status Letter
Extension of Time Request		r of Attorney, Revocation ge of Correspondence Addre	Other Enclosure(s) (please identify below):
Express Abandonment Rec	ujest	nal Disclaimer est for Refund	Return Postcard
☐ Information Disclosure State		lumber of CD(s)	(
Certified Copy of Priority Document(s)	Rem	Remarks The Commissioner is authorized to charge any additional fees Deposit Account 20-1430.	
Response to Missing Parts Incomplete Application	,		
Response to Missing P under 37 CFR 1.52 or			
	SIGNATURE OF	APPLICANT, ATTORNI	EY, OR AGENT
and	Townsend and Townsend and		
Individual name Beth L.	Kelly	R	leg. No. 51,868
Signature	ed C	Wills	
Date Novem	per 25, 2002		

class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: November 25, 2002

Typed or printed name Landon Clark

Signature

Date

November 25, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1409628 v1



Substitute for form 1449B/PTO

Sheet

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known 09/780,114 **Application Number** February 9, 2001 **Filing Date** Nobori, Tsutomu, et. al. **First Named Inventor** 1634 Art Unit Jeanine Anne Goldberg **Examiner Name** 02307O-103031US Attorney Docket Number

DEU 0 5 2002

TECH CENTER 1600/290

-		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	CEN
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BATOVA, et al., "Frequent Deletion in the Methylthioadenosine Phosphorylase Gene in T-Cell Acute Lymphoblastic Leukemia: Strategies for Enzyme-Targeted Therapy," Blood, Vol. 88, No. 8, pp. 3083-3090, (October 15, 1996)	
	AB	CARRERA, et al., "Assignment of The Gene For Methylthioadenosine Phosphorylase to Human Chromosome 9 By Mouse-Human Somatic Cell Hybridization," Proc. Natl. Acad. Sci., Vol. 81, pp. 2665-2668, USA, (May 1984)	
	AC	HORI, et al., " Methylthioadenosine Phosphorylase cDNA Transfection Alters Sensitivity to Depletion of Purine and Methionine in A549 Lung Cancer Cells1," Cancer Research 56, pp. 5653-5658, (December 15, 1996)	
	AD	OLOPADE, et al., "Homozygous Loss of the Interferon Genes Defines the Critical Region on 9p That Is Deleted in Lung Cancers1," Cancer Research 53, pp. 2410-2415, (May 15, 1993)	
	AE	TRAN, et al., "Molecular Cloning of the Human Methylthioadenosine Phosphorylase Processed Pseudogene and Localization to 3q28," Gene 186, pp. 263-269, (1997)	
	AF	TYAGI, et al., "Biochemical Pharmacology, Metabolism, and Mechanism of Action of L-Alanosine, a Novel, Natural Antitumor Agent," Advances in Pharmacology and Chemotherapy, Vol 20, pp. 69-121, (1984)	
	AG	YU, et al., "Presence of Methylthioadenosine Phosphorylase (MTAP) in Hematopoietic Stem/Progenitor Cells: Its Therapeutic Implication for MTAP (-) Malignancies1," Clinical Cancer Research, Vol. 3, pp. 433-438, (March 1997)	
			_

Examiner	Date	
Signature	Considered	i

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1408604 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.